| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R M Philpot, S McQuown, C L Kirstei. Stereotaxic localization of the developing nucleus accumbens septi. Brain research. Developmental brain research. vol 130. issue 1. 2001-12-04. PMID:11557105. |
specifically, few studies have focussed on dopamine (da), its neurochemical pathways and the long-term consequences of manipulating the dopaminergic (daergic) system in the developing animal. |
2001-12-04 |
2023-08-12 |
rat |
| D L Dow-Edwards, Y Busida. Behavioral responses to dopamine agonists in adult rats exposed to cocaine during the preweaning period. Pharmacology, biochemistry, and behavior. vol 70. issue 1. 2001-12-04. PMID:11566139. |
these results suggest that intermittent inhibition of the dopamine transporter with either cocaine or gbr during pnd 11-20 produces long-term alterations in the functional responses of dopaminergic systems but that the neural substrates for these effects depend upon the sex of the animal. |
2001-12-04 |
2023-08-12 |
rat |
| L N Voruganti, P Slomka, P Zabel, A Mattar, A G Awa. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry research. vol 107. issue 3. 2001-12-04. PMID:11566433. |
a comparison of the two sets of images, obtained before and immediately after smoking cannabis, indicated a 20% decrease in the striatal dopamine d2 receptor binding ratio, suggestive of increased synaptic dopaminergic activity. |
2001-12-04 |
2023-08-12 |
Not clear |
| R R Gainetdinov, A R Mohn, L M Bohn, M G Caro. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America. vol 98. issue 20. 2001-12-04. PMID:11572967. |
the dopamine transporter (dat), which reuptakes the released neurotransmitter into presynaptic terminals, is a major determinant of the intensity and duration of the dopaminergic signal. |
2001-12-04 |
2023-08-12 |
mouse |
| R R Gainetdinov, A R Mohn, L M Bohn, M G Caro. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America. vol 98. issue 20. 2001-12-04. PMID:11572967. |
knockout mice lacking the dopamine transporter (dat-ko mice) display marked changes in dopamine homeostasis that result in elevated dopaminergic tone and pronounced locomotor hyperactivity. |
2001-12-04 |
2023-08-12 |
mouse |
| R R Gainetdinov, A R Mohn, L M Bohn, M G Caro. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America. vol 98. issue 20. 2001-12-04. PMID:11572967. |
the pharmacological effect of these drugs occurs without any observable changes in dopaminergic parameters, suggesting that other neurotransmitter systems in addition to dopamine might contribute to the control of locomotion in these mice. |
2001-12-04 |
2023-08-12 |
mouse |
| R R Gainetdinov, A R Mohn, L M Bohn, M G Caro. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America. vol 98. issue 20. 2001-12-04. PMID:11572967. |
these findings support the concept of a reciprocal functional interaction between dopamine and glutamate in the basal ganglia and suggest that agents modulating glutamatergic transmission may represent an approach to manage conditions associated with dopaminergic dysfunction. |
2001-12-04 |
2023-08-12 |
mouse |
| F Liu, X H Ma, J Ule, J A Bibb, A Nishi, A J DeMaggio, Z Yan, A C Nairn, P Greengar. Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors. Proceedings of the National Academy of Sciences of the United States of America. vol 98. issue 20. 2001-12-04. PMID:11572969. |
cyclin-dependent kinase 5 (cdk5) is a multifunctional neuronal protein kinase that is required for neurite outgrowth and cortical lamination and that plays an important role in dopaminergic signaling in the neostriatum through phosphorylation of thr-75 of darpp-32 (dopamine and camp-regulated phosphoprotein, molecular mass 32 kda). |
2001-12-04 |
2023-08-12 |
mouse |
| J G Freeman, J J Ryan, C P Shelburne, D P Bailey, L A Bouton, N Narasimhachari, J Domen, N Siméon, F Couderc, J K Stewar. Catecholamines in murine bone marrow derived mast cells. Journal of neuroimmunology. vol 119. issue 2. 2001-12-04. PMID:11585626. |
neither dopaminergic receptor antagonists nor exogenous dopamine < or =10 microm affected il-3-induced cell proliferation. |
2001-12-04 |
2023-08-12 |
Not clear |
| B M Campbell, P J Gresch, P D Walke. Neonatal dopamine depletion reveals a synergistic mechanism of mRNA regulation that is mediated by dopamine(D1) and serotonin(2) receptors and is targeted to tachykinin neurons of the dorsomedial striatum. Neuroscience. vol 105. issue 3. 2001-11-01. PMID:11516832. |
it has been hypothesized that dopamine(d1) and serotonin(2) receptors become sensitized to agonist-mediated regulation of gene expression following loss of dopaminergic innervation to the striatum. |
2001-11-01 |
2023-08-12 |
rat |
| A Desautels, G Turecki, J Montplaisir, N Ftouhi-Paquin, M Michaud, V A Chouinard, G A Roulea. Dopaminergic neurotransmission and restless legs syndrome: a genetic association analysis. Neurology. vol 57. issue 7. 2001-11-01. PMID:11591853. |
in order to examine the genetic substrate of the dopamine hypothesis in restless legs syndrome, we analyzed eight genes coding for receptors and enzymes related to dopaminergic transmission, using a population of 92 patients with restless legs syndrome and 182 controls matched for ethnic background. |
2001-11-01 |
2023-08-12 |
Not clear |
| J Lavalaye, A Sarlet, J Booij, D H Linszen, L Reneman, B P Gersons, E A van Roye. Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study. Psychopharmacology. vol 155. issue 1. 2001-10-25. PMID:11374328. |
it may be caused by loss of dopaminergic cells, due to free radicals as a product of high synaptic dopamine levels. |
2001-10-25 |
2023-08-12 |
Not clear |
| E Izzo, C Orsini, G F Koob, L Pulvirent. A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule. Pharmacology, biochemistry, and behavior. vol 68. issue 4. 2001-10-25. PMID:11526967. |
these drugs bind to dopamine receptors with high affinity and low intrinsic activity and are thought to behave as functional antagonists in conditions of high dopaminergic tone, and as agonists in conditions of low receptor occupancy by dopamine. |
2001-10-25 |
2023-08-12 |
Not clear |
| A Gjedd. [Receptor mapping in living human beings by means of positron emission tomography]. Ugeskrift for laeger. vol 163. issue 38. 2001-10-25. PMID:11577527. |
pet has revealed loss of dopaminergic terminals and dopamine synthetic capacity in parkinson's disease, mptp intoxication, and lesch-nyhan's syndrome; release of dopamine after administration of cocaine and amphetamine, and in motor activity and cognition; increased synaptic dopamine and release of dopamine, and the 70-90% neuroleptic occupancy of dopamine receptors in the striatum, in patients with schizophrenia; loss of muscarinic and nicotinergic receptors in alzheimer's disease, and benzodiazepine and opiate receptors in stroke, epilepsy, and huntington's chorea; altered opiate receptors in chronic pain and drug abuse; and release of opiates in analgesia; but changes in serotonin synthesis, transport, and binding in affective or psychotic disorders remain elusive. |
2001-10-25 |
2023-08-12 |
human |
| J R Jenkin. Feather picking and self-mutilation in psittacine birds. The veterinary clinics of North America. Exotic animal practice. vol 4. issue 3. 2001-10-25. PMID:11601106. |
on a chemical level, stereotypic behavior appears to be related to an increased dopaminergic activity and an increased dopamine turnover. |
2001-10-25 |
2023-08-12 |
Not clear |
| S Nishino, J Mao, R Sampathkumaran, J Shelto. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep research online : SRO. vol 1. issue 1. 2001-10-18. PMID:11382857. |
in order to evaluate the relative importance of dopaminergic and noradrenergic transmission in the mediation of these effects, five dopamine (da) uptake inhibitors (mazindol, gbr-12909, bupropion, nomifensine and amineptine), two norepinephrine (ne) uptake inhibitors (nisoxetine and desipramine), d-amphetamine, and modafinil, a non-amphetamine stimulant, were tested in control and narcoleptic canines. |
2001-10-18 |
2023-08-12 |
Not clear |
| J P Larsen, E Tandber. Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS drugs. vol 15. issue 4. 2001-10-18. PMID:11463132. |
sleep attacks are observed in patients treated with all dopaminergic medications but have recently been brought to prominence because of their association with the newer dopamine agonists ropinirole and pramipexole. |
2001-10-18 |
2023-08-12 |
Not clear |
| R M Care. Theodore Cooper Lecture: Renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension (Dallas, Tex. : 1979). vol 38. issue 3. 2001-10-18. PMID:11566894. |
in experimental and human hypertension, 2 renal dopaminergic defects have been described: (1) decreased renal generation of dopamine and (2) a d(1) receptor-g protein coupling defect. |
2001-10-18 |
2023-08-12 |
human |
| K Nakamura, V P Bindokas, D Kowlessur, M Elas, S Milstien, J D Marks, H J Halpern, U J Kan. Tetrahydrobiopterin scavenges superoxide in dopaminergic neurons. The Journal of biological chemistry. vol 276. issue 37. 2001-10-11. PMID:11447224. |
we hypothesize that bh(4) protects dopaminergic neurons from ordinary oxidative stresses generated by dopamine and its metabolites and that environmental insults or genetic defects may disrupt this intrinsic capacity of dopaminergic neurons and contribute to their degeneration in parkinson's disease. |
2001-10-11 |
2023-08-12 |
Not clear |
| L M Cancela, A M Basso, I D Martijena, N R Capriles, V A Molin. A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study. Brain research. vol 909. issue 1-2. 2001-10-11. PMID:11478934. |
altogether, these results suggest that: (1) previous exposure to chronic amph treatment induces an increased emotional response following a conflict situation, (2) dopamine d(1) receptors are mainly involved in chronic amph-induced changes in the behavior displayed in epm test, and (3) an interaction between gabaergic and dopaminergic mechanisms may be implicated in neurochemical and behavioral changes induced by chronic amph treatment. |
2001-10-11 |
2023-08-12 |
rat |